Linotar Psoriasis Medication
  International Distributor
Call us Toll Free in North America
US / Canada: 1-888-604-4561


Linotar Psoriasis Medication

Linotar Gel 1%: Product Profile

Linotar Gel 1% (also known as Exorex® Gel 1% penetrating emulsion) is a highly innovative topical dermatological preparation indicated for the treatment of Psoriasis and Eczema. The active ingredient is distilled coal tar. In addition, Linotar Gel 1% features a sophisticated vehicle consisting of a specific combination of free essential fatty acids. Linotar, as a result, has been successfully applied without most of the burdens that are usually associated with the use of more conventional, coal tar preparations.

Contrary to most traditional coal tar preparations, Linotar Gel 1% produces an extremely rapid and almost complete penetration (1). The excipients have a transdermal carrier function, bringing coal tar much more efficiently through the affected skin. Thanks to this special feature and due to the general physical properties of Linotar Moisturising Cream, the product does not provoke as much of the yellow staining that is common to coal tar products, nor does it produce the traditional strong coal tar smell: The product "disappears" within minutes.

Linotar has been developed by Meyer Zall Laboratories of South Africa and was first launched in 1993 in its home market, South Africa, for both the indications Psoriasis and Eczema, as part of a complete treatment method.Since 1993, Its equivalent, Exorex®, has been successfully introduced in Australia, New Zealand, and in a number of African and Asian countries, as well as in the U.S.A., Canada, Israel, Ireland and the United Kingdom. In 1996 Exorex® 1% was registered in Austria, Greece, The Netherlands and Luxembourg.

Exorex® 1% has been shown to be clinically and statistically equally effective as the vitamin D derivate calcipotriol (also known as Daivonex®, Dovonex® or Psorcutan® Creme) and superior to any coal tar in the treatment of psoriasis, through objective parameters and in patient preference scores. Results of a recently completed Austrian (University of Vienna, 2001) 40-patient clinical trial proves this point (2). These results closely match those of an earlier 18-patient US pilot study in which Exorex® is compared with the vitamin D derivate Dovonex (calcipotriene) (3).

(1) For further information on the trans dermal carrier, go to: